Oncology unit revenues increased 11% operationally in comparison with fourth-quarter 2011. Revenues were positively impacted by the launches of Inlyta and Xalkori in the U.S. and certain other developed markets. Revenues were negatively impacted by approximately $44 million, or 13%, due to the shift in the reporting of international Aromasin revenues to the Established Products unit beginning January 1, 2012.
Consumer Healthcare unit revenues increased 17% operationally in comparison with fourth-quarter 2011, primarily due to the addition of products from the acquisitions of Ferrosan Consumer Health in December 2011 and Alacer Corp. in February 2012 as well as strong growth of Advil and Centrum in the U.S.
Adjusted Expenses (2) , Adjusted Income (2) and Adjusted Diluted EPS (2) Highlights
|Fourth-Quarter Selected Costs and Expenses|
| ($ in millions)
|Adjusted Cost of Sales (2)||$||3,106||$||3,083||1||%||8||%||(7||%)|
|As a Percent of Revenues||20.6||%||19.1||%||N/A||N/A||N/A|
|Adjusted SI&A Expenses (2)||4,658||5,173||(10||%)||(1||%)||(9||%)|
|Adjusted R&D Expenses (2)||2,000||2,318||(14||%)||(1||%)||(13||%)|
See end of text prior to tables for notes.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts